These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
228 related articles for article (PubMed ID: 30309370)
21. Neonatal screening for inborn errors of metabolism: cost, yield and outcome. Pollitt RJ; Green A; McCabe CJ; Booth A; Cooper NJ; Leonard JV; Nicholl J; Nicholson P; Tunaley JR; Virdi NK Health Technol Assess; 1997; 1(7):i-iv, 1-202. PubMed ID: 9483160 [TBL] [Abstract][Full Text] [Related]
22. Projected cost-effectiveness of statewide universal newborn hearing screening. Keren R; Helfand M; Homer C; McPhillips H; Lieu TA Pediatrics; 2002 Nov; 110(5):855-64. PubMed ID: 12415021 [TBL] [Abstract][Full Text] [Related]
23. Adrenoleukodystrophy in the era of newborn screening. Eng L; Regelmann MO Curr Opin Endocrinol Diabetes Obes; 2020 Feb; 27(1):47-55. PubMed ID: 31789721 [TBL] [Abstract][Full Text] [Related]
25. Improved analysis of C26:0-lysophosphatidylcholine in dried-blood spots via negative ion mode HPLC-ESI-MS/MS for X-linked adrenoleukodystrophy newborn screening. Haynes CA; De Jesús VR Clin Chim Acta; 2012 Aug; 413(15-16):1217-21. PubMed ID: 22503909 [TBL] [Abstract][Full Text] [Related]
26. The experiences of parents of children diagnosed with cerebral adrenoleukodystrophy. Piercy H; Nutting C Child Care Health Dev; 2024 Jan; 50(1):e13184. PubMed ID: 37850425 [TBL] [Abstract][Full Text] [Related]
27. Newborn Screening for X-Linked Adrenoleukodystrophy. Moser AB; Jones RO; Hubbard WC; Tortorelli S; Orsini JJ; Caggana M; Vogel BH; Raymond GV Int J Neonatal Screen; 2016 Dec; 2(4):. PubMed ID: 31467997 [TBL] [Abstract][Full Text] [Related]
28. The Changing Face of Adrenoleukodystrophy. Zhu J; Eichler F; Biffi A; Duncan CN; Williams DA; Majzoub JA Endocr Rev; 2020 Aug; 41(4):577-93. PubMed ID: 32364223 [TBL] [Abstract][Full Text] [Related]
29. Clinical effectiveness and cost-effectiveness of neonatal screening for inborn errors of metabolism using tandem mass spectrometry: a systematic review. Pandor A; Eastham J; Beverley C; Chilcott J; Paisley S Health Technol Assess; 2004 Mar; 8(12):iii, 1-121. PubMed ID: 14982654 [TBL] [Abstract][Full Text] [Related]
30. Newborn screening for X-linked adrenoleukodystrophy in New York State: diagnostic protocol, surveillance protocol and treatment guidelines. Vogel BH; Bradley SE; Adams DJ; D'Aco K; Erbe RW; Fong C; Iglesias A; Kronn D; Levy P; Morrissey M; Orsini J; Parton P; Pellegrino J; Saavedra-Matiz CA; Shur N; Wasserstein M; Raymond GV; Caggana M Mol Genet Metab; 2015 Apr; 114(4):599-603. PubMed ID: 25724074 [TBL] [Abstract][Full Text] [Related]
31. Early Detection of Adrenal Insufficiency: The Impact of Newborn Screening for Adrenoleukodystrophy. Ramirez Alcantara J; Grant NR; Sethuram S; Nagy A; Becker C; Sahai I; Stanley T; Halper A; Eichler FS J Clin Endocrinol Metab; 2023 Oct; 108(11):e1306-e1315. PubMed ID: 37220095 [TBL] [Abstract][Full Text] [Related]
32. Retrospective evaluation of patients with X-linked adrenoleukodystrophy with a wide range of clinical presentations: a single center experience. Olgac A; Kasapkara ÇS; Derinkuyu B; Yüksel D; Çetinkaya S; Aksoy A; Ceylaner S; Güleray N; Yeşilipek A; Aydın Hİ; Orgun LT; Kılıç M J Pediatr Endocrinol Metab; 2021 Sep; 34(9):1169-1179. PubMed ID: 34162029 [TBL] [Abstract][Full Text] [Related]
33. Liquid chromatography-tandem mass spectrometry method for estimation of a panel of lysophosphatidylcholines in dried blood spots for screening of X-linked adrenoleukodystrophy. Natarajan A; Christopher R; Netravathi M; Bhat M; Chandra SR Clin Chim Acta; 2018 Oct; 485():305-310. PubMed ID: 30018013 [TBL] [Abstract][Full Text] [Related]
34. Modeling and rescue of defective blood-brain barrier function of induced brain microvascular endothelial cells from childhood cerebral adrenoleukodystrophy patients. Lee CAA; Seo HS; Armien AG; Bates FS; Tolar J; Azarin SM Fluids Barriers CNS; 2018 Apr; 15(1):9. PubMed ID: 29615068 [TBL] [Abstract][Full Text] [Related]
35. A Cost-Effectiveness Analysis of Newborn Screening for Severe Combined Immunodeficiency in the UK. Bessey A; Chilcott J; Leaviss J; de la Cruz C; Wong R Int J Neonatal Screen; 2019 Sep; 5(3):28. PubMed ID: 33072987 [TBL] [Abstract][Full Text] [Related]
36. Flow injection ionization-tandem mass spectrometry-based estimation of a panel of lysophosphatidylcholines in dried blood spots for screening of X-linked adrenoleukodystrophy. Natarajan A; Christopher R; Netravathi M; Bhat MD; Chandra SR Clin Chim Acta; 2019 Aug; 495():167-173. PubMed ID: 30980791 [TBL] [Abstract][Full Text] [Related]
37. Application of a diagnostic methodology by quantification of 26:0 lysophosphatidylcholine in dried blood spots for Japanese newborn screening of X-linked adrenoleukodystrophy. Wu C; Iwamoto T; Igarashi J; Miyajima T; Hossain MA; Yanagisawa H; Akiyama K; Shintaku H; Eto Y Mol Genet Metab Rep; 2017 Sep; 12():115-118. PubMed ID: 28725571 [TBL] [Abstract][Full Text] [Related]
38. Economic evaluation of point of care universal newborn screening for glucose-6-Phosphate dehydrogenase deficiency in United States. Vidavalur R; Bhutani VK J Matern Fetal Neonatal Med; 2022 Dec; 35(25):5745-5753. PubMed ID: 33627013 [TBL] [Abstract][Full Text] [Related]
39. Economic evaluation of tandem mass spectrometry screening in California. Feuchtbaum L; Cunningham G Pediatrics; 2006 May; 117(5 Pt 2):S280-6. PubMed ID: 16735254 [TBL] [Abstract][Full Text] [Related]
40. Clinical evaluation of childhood cerebral adrenoleukodystrophy with balint's symptoms. Kubota K; Kawai H; Takashima S; Shimohata T; Otsuki M; Ohnishi H; Shimozawa N Brain Dev; 2021 Mar; 43(3):396-401. PubMed ID: 33309491 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]